Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Prostate Adenocarcinoma × flibanserin × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostate Adenocarcinoma 1 Breast Neoplasms 1

Interventions

luprolide acetate gel depot 3 Magnetic Resonance Spectroscopy 3 Specimen Handling 2 Leuprolide 2 Goserelin 2 Biopsy 2 relugolix 1 radium Ra 223 dichloride 1 niraparib 1 gallium 68 PSMA-11 1 fluciclovine F-18 1 flibanserin 1 enzalutamide 1 atezolizumab 1 apalutamide 1 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 abiraterone 1 X-Rays 1 Triptorelin Pamoate 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Radiosurgery 1 Radiation 1 Prednisone 1 PROSTVAC 1 Methods 1 Lymph Node Excision 1 Glutamate Carboxypeptidase II 1 Estramustine 1 Educational Status 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04743934 2025-05-04

RAD 2003

University of Alabama at Birmingham

Phase 2 Active not recruiting

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡